Search Results - patricia+dranchak

3 Results

Sort By:

Development of a Therapy for the Treatment of Zellweger Spectrum Disorder

This technology includes a method for selecting a therapeutic effective amount of one of two compounds (including naltriben and naltrin) for the treatment of Zellweger Spectrum Disorder (ZSD), or any disease associated with peroxisome dysfunction. The compounds were identified using a cell-image based high-content screening (HCS) assay to identify small...

Published: 7/25/2024 | Inventor(s): Patricia Dranchak, James Inglese

Keywords(s): DEVELOP, DISORDER, Spectrum, THERAPY, TOOLS, treatment, VEXXXX, WIXXXX, WKXXXX, Zellweger

Category(s): TherapeuticArea > Neurology, Application > Therapeutics, Application > Research Materials

Potential New Drugs for Treating or Preventing Pruritus

NIH scientists have identified new compositions that could potentially be used to treat or prevent pruritus (itchiness). The newly discovered compounds can block a newly identified itch pathway and might be effective for persistent itch caused by psoriasis, atopic dermatitis, renal failure, liver cirrhosis and chemotherapy. These compounds are different...

Published: 7/25/2024 | Inventor(s): Hans Solinski, James Inglese, Patricia Dranchak, Mark Hoon

Keywords(s): BLOCKAGE, IB6XXX, Itch, Listed LPM Vepa as of 4/15/2015, Nppb, Npr1, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, Sensation, TRANSMITTER, treatment, VOXXXX, VPXXXX, WKXXXX, XHXXXX, YAXXXX, YBXXXX, YCXXXX

Category(s): TherapeuticArea > Reproductive Health, TherapeuticArea > Oncology, Application > Consumer Products, TherapeuticArea > Infectious Disease, ResearchProducts > Research Equipment, TherapeuticArea > Ophthalmology, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, TherapeuticArea > Cardiology

Potent and Selective Cyclic Peptide Inhibitors of Phosphoglycerate Mutase as Anti-Infective Agents

Summary – The invention includes compounds and compositions for inhibiting phosphoglycerate mutase (PGM) activity. In some examples, the compounds selectively inhibit cofactor-independent PGM (iPGM). In particular embodiments, the compounds include one or more cyclic peptides. Brief Background – Co-factor independent phosphoglycerate mutase (iPGM)...

Published: 7/25/2024 | Inventor(s): Patricia Dranchak, Ryan Macarthur, James Inglese

Keywords(s): Agents, Anti-infective, Cyclic, DB2XXX, DB3XXX, Inhibitors, Mutase, Peptide, Phosphoglycerate, POTENT, SELECTIVE, VJXXXX, VQXXXX

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics